- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07301151
PASCAL Feasibility Study
Feasibility of Using a Conversational Agent for Promoting Smoking Cessation Treatment Utilization
The goal of this randomized study is to assess if a conversational agent (or chatbot) that the investigators have developed to help with quitting smoking is acceptable to people trying to quit smoking and to also collect initial information regarding its effectiveness.
In this study, some participants trying to quit smoking will be provided with this chatbot while other participants will not be
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sheena Study Coordinator
- Phone Number: 612-626-5981
- Email: gahmx008@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Identify as Black or African American
- Be at least 21 years of age
- Meet a minimum smoking amount
- Be willing to make a quit attempt in the next 30 days
- Have a smartphone capable of downloading and running the study app
- Be able to upload data from the app
- Agree to receive text message reminders about study activities
- Be a native English speaker
- Reside in Minnesota.
Exclusion Criteria:
- Medicinal nicotine use would require careful monitoring by a healthcare professional
- Medical condition or medication used likely to significantly interfere with study outcomes or to be significantly affected by changes in smoking behavior
- Are pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: control group
|
no chatbot is provided
|
|
Experimental: chatbot assisted smoking trigger management
|
a chatbot will alert during predicted high risk smoking times and suggest approaches to manage potential smoking triggers
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of trial procedures
Time Frame: 1 day
|
The proportion of enrolled participants who download the study app
|
1 day
|
|
Feasibility of study procedures
Time Frame: 2 weeks
|
The proportion of participants (among those who downloaded the app) who complete the week 2 post-quit visit
|
2 weeks
|
|
Health Information Technology Usability Evaluation Scale (Health-ITUES)
Time Frame: 2 weeks
|
This scale will be used to access the acceptability of study app.
The scale consists of 20 questions scored from 1 to 5 with higher values indicating more positive response
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average number of daily interactions with the study app
Time Frame: 2 weeks
|
2 weeks
|
|
|
The average number of cigarettes smoked per day
Time Frame: 2 weeks
|
2 weeks
|
|
|
Average number of nicotine lozenges used
Time Frame: 2 weeks
|
2 weeks
|
|
|
The proportion of participants who complete the week 8 post-quit visit
Time Frame: 8 weeks
|
8 weeks
|
|
|
The proportion of participants not smoking for the 7 day period before the week 2 visit
Time Frame: 2 weeks
|
2 weeks
|
|
|
The proportion of participants not smoking for the 7 day period before the week 8 visits
Time Frame: 8 weeks
|
8 weeks
|
|
|
The proportion of participants not smoking at all between the quit date and the week 2 visit
Time Frame: 2 weeks
|
2 weeks
|
|
|
The proportion of participants not smoking at all between the quit date and the week 8 visit
Time Frame: 8 weeks
|
8 weeks
|
|
|
Motivation to quit smoking
Time Frame: 2 weeks
|
Using a 1 - 10 scale on the contemplation to quit ladder (1 - no interest in quitting; 10 - will never smoke again)
|
2 weeks
|
|
Brief Questionnaire of Smoking Urges (QSU-Brief)
Time Frame: 2 weeks
|
Questionnaire assessing craving severity.
Range for total score is 10 - 70 with higher score indicating greater craving
|
2 weeks
|
|
The Minnesota Nicotine Withdrawal Scale (MNWS)
Time Frame: 2 weeks
|
Questionnaire assessing withdrawal symptom severity.
Range for total score is 0 - 36 with higher score indicating greater withdrawal symptoms
|
2 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Kotlyar, University of Minnesota
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00026782
- P50MD017342 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
National University of SingaporeRecruitingSmoking &Amp; Tobacco CessationSingapore
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedSmoking &Amp; Tobacco CessationUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Sultan Qaboos UniversityCompletedSmoking Cessation | Tobacco Use Cessation | Smoking PreventionOman
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
Clinical Trials on chatbot
-
Distrito Sanitario AlmeriaJunta de AndaluciaRecruitingDigital Health | Workplace Violence | Health Professionals | ChatbotSpain
-
University of UtahHuntsman Cancer InstituteNot yet recruitingCancer | Financial ToxicityUnited States
-
University of UtahAmerican Cancer Society, Inc.Recruiting
-
University of Maryland, College ParkCompletedCervical Cancer | Anal Cancer | Penile CancerUnited States
-
University of California, IrvineNational Center for Complementary and Integrative Health (NCCIH)Not yet recruitingMajor Depressive Disorder | Generalized Anxiety Disorder (GAD)
-
Hong Kong Metropolitan UniversityRecruitingAutism Spectrum DisorderHong Kong
-
Cheng-Hsin General HospitalRecruitingLower Urinary Tract Symptoms | Erectile Dysfunction | Benign Prostate EnlargementTaiwan
-
Abramson Cancer Center at Penn MedicineActive, not recruitingHead and Neck Cancer | Lung Cancer | Gastrointestinal CancerUnited States
-
University of Central FloridaOrlando Regional Medical Center; American Epilepsy Society; Orlando Health Arnold...RecruitingEpilepsy | SeizureUnited States
-
Yonsei UniversityCompletedBreast NeoplasmsKorea, Republic of